Disposition and exposure of the fibrinogen receptor antagonist XV459 on α(IIB)β3 binding sites in the guinea pig

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 6, 1999, Pages 309-318

  Barrett, Jeffrey S ^a   Yu, Jun ^a   Kapil, Ram ^a   Padovani, Patricia ^a   Brown, Foster ^a   Ebling, William F ^a   Corjay, Martha H ^a   Reilly, Thomas M ^a   Bozarth, Jeffrey M ^a   Mousa, Shaker A ^a   Pieniaszek Jr , Henry J ^a  

^a DUPONT COMPANY   (United States)

Author keywords

DMP 754; GP IIb IIIa; Guinea pig; Pharmacokinetics; Roxifiban; XV459

Indexed keywords

3 [[[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETYL]AMINO] N (BUTOXYCARBONYL)ALANINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; GUINEA PIG; HUMAN; MALE; NONHUMAN; THROMBOCYTE AGGREGATION;

AMINO ACIDS; ANIMALS; AREA UNDER CURVE; BINDING SITES; BINDING, COMPETITIVE; GUINEA PIGS; HUMANS; INFUSIONS, INTRAVENOUS; ISOXAZOLES; MALE; METABOLIC CLEARANCE RATE; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 17344375184     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199909)20:6<309::AID-BDD190>3.0.CO;2-7     Document Type: Article

References (31)

1. Mousa SA, Forsythe MS, Lorelli W, Bozarth JM, Xue CB, Wityak J, Sielecki TM, Olson RE, DeGrado WM, Kapil RP, Wexler R, Thoolen MJ, Reilly TM. Novel nonpeptide antiplatelet GPIIb/IIIa receptor antagonist, DMP 754: receptor binding affinity and specificity. Coron Artery Dis 1996; 7: 57-64.
2. Mousa SA, Kapil R, Mu D-X. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459. Arterioscler Thromb Vasc Biol 1999; 19: 2535-2541.
3. Kapil RP, Padovani PK, Garner DM, Chien BM, Quon CY, Lam GN. Nonlinear pharmacokinetics of a novel platelet glycoprotein IIb/IIIa receptor antagonist, XV459, in beagle dogs. Pharm Res 1996; 13: S-497.
4. Kapil RP, Emm TA, Mousa SA, Padovani PK, Quon CY, Lam GN. Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel platelet glycoprotein IIb/IIIa receptor antagonist, XU063, in beagle dogs. Pharm Res 1997; 14: S-356.
5. Kapil RP, Emm TA, Mousa SA, Padovani PK, Quon CY, Lam GN. Biological matrix-dependent pharmacokinetic and pharmadynamic parameters of a novel antiplatelet agent, XU063, in beagle dogs. Thromb Res 1997; 86: 221-232.
6. André P, Arbeille B, Drouet V, Hainaud P, Bal dit Sollier C, Caen JP, Drouet LO. Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth: an ex vivo capillary perfusion chamber study in the guinea pig. Arterioscler Thromb Vasc Biol 1996; 16: 56-63.
7. Roux S, Carteaux JP, Hess P, Falivene L, Clozel JP. Experimental cartoid thrombosis in the guinea pig. Thromb Haemost 1994; 71: 252-256.
8. Umemura K, Nishiyama H, Kikuchi S, Kondo K, Nakashima M. Inhibitory effect of a novel orally active GP IIb/IIIa inhibitor, SC-54684 on intimal thickening in the guinea pig femoral artery. Thromb Haemost 1996; 76: 799-806.
9. Gold HK, Gimple LW, Yasuda T. Pharmacodynamic study of F(ab′)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86: 651-659.
10. Barrett JS, Murphy MG, Peerlink K, De Lepeleire I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermylen J, Arnout J. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet GP IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 1994; 56: 377-388.
11. Barrett JS, Ghannam A, Hand E, Sax FL. Designing consecutive infusion regimens for IV fibrinogen receptor antagonist phase IIa studies in CAD patients based on phase-I PK/PD. Pharm Res 1993; 10: S-368.
12. Narjes H, Muller TH, Weisenberger H, Guth B, Brickl R. Inhibition of platelet aggregation as a surrogate marker. J Clin Pharmacol 1997; 37: 59S-64S.
13. Mordenii J, Rescigno A. Theoretical considerations for the design and development of a drug: influence of pharmacokinetics and dosage regimen on receptor interactions. Pharm Res 1993; 10: 777-782.
14. Kawamura M, Imura Y, Moriya N, Kita S, Fukushi H, Sugihara H, Mishikawa K, Terashita Z-I. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban. J Pharmacol Exp Ther 1996; 277: 502-510.
15. Burke SE, Lefer AM, Nicolaou KC, Smith GM, Smith B. Responsiveness of platelets and coronary arteries from different species to synthetic thromboxane and prostaglandin endoperoxide analogues. Br J Pharmacol 1983; 78: 287-292.
16. Chiu PSJ, Tetzloff GG, Foster C, Chintala M, Sybertz EJ. Characterization of in vitro and in vivo platelet responses to thrombin and thrombin receptor-activating peptides in guinea pigs. Eur J Pharmacol 1997; 321: 129-135.
17. Hussain M, Aungst B, Kapil RP, Mousa S. Intranasal absorption of the platelet glycoprotein IIb/IIIa antagonist DMP 755 and the effect of anesthesia on nasal bioavailabiliry. J Pharm 1997; 86: 1358-1360.
18. Mousa S, Olson RH, Bozarth J, Lorelli W, Forsythe MS, Racanelli A, Gibbs S, Schlingman K, Bozarth T, Kapil RP, Wityak J, Sielecki TM, Wexler RR, Thoolen MJ, Slee A, Reilly TM, Anderson PS, Friedman PA. Oral antiplatelet efficacy and specificity of a novel non-peptide platelet GPIIb/IIIa receptor antagonist, DMP 802. J Cardiovasc Pharmacol 1998; 32: 169-176.
19. Martin JF, Trowbridge EA, Salmon G, Plumb J. The biological significance of platelet volume: its relationship to bleeding time platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983; 32: 443-460.
20. Martin JF, Plumb J, Kilbey RS, Kishk YT. Changes in volume and density of platelets in myocardial infarction. Br Med J 1983; 287: 449-452.
21. Sewell R, Ibbotson RM, Phillips R, Carson P. High mean platelet volume after myocardial infarction: is it due to consumption of small platelets. Br Med J 1984; 289: 1576-1578.
22. Mousa S, Bozarth J, Forsythe M, Jackson S, Leamy A, Diemer M, Kapil R, Knabb R, Mayo M, Pierce S, De Grado W, Thoolen M, Reilly T. Antiplatelet, antithrombotic efficacy of DMP728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation 1994; 89: 3-12.
23. Mousa S, Bozarth J, Forsythe M, Lorelli W, Jackson S, Ramachandran N, De Grado W, Thoolen M, Reilly T. Antiplatelet efficacy and specificity of a novel platelet GPIIb/IIIa receptor antagonist, DMP728. Cardiology 1993; 83: 374-382.
24. i) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-3108.
25. Osmond DG, Everett NB. Bone marrow blood volume and total red cell mass of the guinea pig as determined by 59Fe-erythrocyte dilution and liquid nitrogen freezing. Q J Exp Physiol 1965; 50: 1-14.
26. Banks R. USAMRIID Seminar Series. The guinea pig: biology, care, identification, nomenclature, breeding, and genetics. 1989 (http://netvet.wustl.edu/species/GUINEA/GUINPIG.TXT).
27. Cook NS, Bruttger O, Pally C, Hagenbach A. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active. Thromb Haemost 1993; 70: 838-847.
28. Cook NS, Zerwes H-G, Tapparelli C, Powling M, Singh J, Metternich R, Hagenbach A. Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea pig, hamster and rat blood: activation by ADP and thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists. Thromb Haemost 1993; 70: 531-539.
29. Eason CT, Pattison A, Howells DD, Mitcheson J, Banner FW. Platelet population profiles: significance of species variation and drug induced changes. J Appl Tox 1986; 6: 437-441.
30. Ebling WF, Kornhauser DM, Ma S, Oliver JS, Pieniaszek HJ Jr. The influence of food and fasting duration on the pharmacokinetics and pharmacodynamics of roxifiban, a glycoprotein IIb/IIIa antagonist. J Clin Pharmacol 1999; 39: 983.
31. Daly R, Ebling W, Pieniaszek H, Cain V, Kopecky S, Murphy J. Roxifiban, a new oral IIb/IIIa glycoprotein receptor antagonist, in patients with coronary artery disease. Lancet Conference Proceedings: The Challenge of Acute Coronary Syndromes, June 10-11, 1999.